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ABSTRACT
Objective To summarise the methodological aspects in 
studies with work participation (WP) as outcome domain in 
inflammatory arthritis (IA) and other chronic diseases.
Methods Two systematic literature reviews (SLRs) were 
conducted in key electronic databases (2014–2019): 
search 1 focused on longitudinal prospective studies 
in IA and search 2 on SLRs in other chronic diseases. 
Two reviewers independently identified eligible studies 
and extracted data covering pre- defined methodological 
areas.
Results In total, 58 studies in IA (22 randomised 
controlled trials, 36 longitudinal observational studies) 
and 24 SLRs in other chronic diseases were included. WP 
was the primary outcome in 26/58 (45%) studies. The 
methodological aspects least accounted for in IA studies 
were as follows (proportions of studies positively adhering 
to the topic are shown): aligning the studied population 
(16/58 (28%)) and sample size calculation (8/58 (14%)) 
with the work- related study objective; attribution of WP 
to overall health (28/58 (48%)); accounting for skewness 
of presenteeism/sick leave (10/52 (19%)); accounting for 
work- related contextual factors (25/58 (43%)); reporting 
attrition and its reasons (1/58 (2%)); reporting both 
aggregated results and proportions of individuals reaching 
predefined meaningful change or state (11/58 (16%)). 
SLRs in other chronic diseases confirmed heterogeneity 
and methodological flaws identified in IA studies without 
identifying new issues.
Conclusion High methodological heterogeneity was 
observed in studies with WP as outcome domain. 
Consensus around various methodological aspects 
specific to WP studies is needed to improve quality of 
future studies. This review informs the EULAR Points to 
Consider for conducting and reporting studies with WP as 
an outcome in IA.
INTRODUCTION
Inflammatory arthritis (IA) encompasses a 
group of chronic diseases typically affecting 
adults in working age, and often leading to 
work disability with consequent loss of income 
Key messages
What is already known about this subject?
 ► Inflammatory arthritis (IA) has substantial impact on 
work participation (WP).
 ► Previous systematic literature reviews of studies 
with WP as an outcome documented deficiencies 
in the study design, analysis and reporting of re-
sults, hampering interpretation, comparison and 
meta- analysis.
What does this study add?
 ► This study provides a synthesis of the methodolog-
ical choices and issues in studies with WP as an 
outcome domain in IA and in other chronic diseases.
 ► Methodological heterogeneity and flaws were iden-
tified across four key areas of potential concern: (1) 
study design, (2) outcome domains and measure-
ment instruments, (3) data analysis and (4) reporting 
of results.
How might this impact on clinical practice?
 ► This study aims to inform the efforts to improve the 
methodological quality and homogeneity of future 
studies with WP as an outcome domain, and ulti-
mately contribute to high- quality evidence on inter-
ventions to support endurable WP.
 ► This review informs the EULAR Points to Consider 
when designing, analysing and reporting studies 
with WP as an outcome domain in IA.
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for patients and high social expenditures for society.1 
The treatment of IA aims at reaching remission or, at 
least, low disease activity in order to prevent structural 
damage and improve patients’ quality of life. Despite the 
proven efficacy of new therapies such as biologic (b) and 
targeted synthetic (ts) disease- modifying anti- rheumatic 
drugs (DMARDs), the burden of restricted participation 
in work remains high.
People living with IA have identified the ability to main-
tain a job and being productive while at work as a priority, 
ranked right after suppressing pain and improving phys-
ical function.2 Work participation (WP) is defined as an 
active engagement in the role of worker.3 In addition 
to the employment status (being employed or not), 
restrictions in work participation can be quantified using 
absenteeism (namely sick leave) and presenteeism.4 
Absenteeism refers to the time missed from work due to 
health reasons and presenteeism refers to experienced 
restrictions or impaired productivity while at work due 
to health reasons.4 People can transition back and forth 
between not working, working with difficulty and working 
without difficulty.5
To ensure effective interventions to support endurable 
WP, high- quality evidence is required. However, several 
systematic literature reviews in IA showed inconclusive 
results that could be partially attributed to methodolog-
ical issues in the study design, analysis and reporting of 
results hampering correct interpretation, comparison 
and meta- analysis of studies.6 7
WP is increasingly seen as an important outcome 
of interventions and thus as a target for improvement. 
During the past decade, the Outcome Measures in Rheu-
matology (OMERACT) Productivity Working Group 
focused its work on evaluating and improving the validity 
of outcomes and outcome measurement instruments 
of WP.4 8–10 Despite its continuous efforts to harmonise 
measurement of worker productivity loss across studies, 
valid instruments are not sufficient to ensure high- quality 
clinical studies.
The primary aim of this systematic literature review 
(SLR) was to inform the EULAR task force working on 
‘points to consider when designing, analysing and reporting 
studies with WP as an outcome domain among patients with 
IA’. The specific objectives of the present work were (1) 
to summarise the methodological choices in studies with 
WP as an outcome domain in IA and (2) to identify the 
methodological issues reported in SLRs of studies with 
WP as an outcome domain in other chronic diseases.
METHODS
Search strategy and eligibility criteria
EULAR task force working on ‘points to consider when 
designing, analysing and reporting studies with WP as an 
outcome domain among patients with IA’ outlined the scope 
of the literature search and pre- identified 24 topics in 
seven main areas of potential concern: (1) study design, 
(2) outcome domains, (3) outcome measurement instru-
ments, (4) contextual factors, (5) data analysis, (6) 
reporting of results and (7) estimating productivity costs. 
These topics were based on (a) knowledge of the litera-
ture and experience with conducting such studies and 
(b) potential role of the issues on bias (selection, infor-
mation and statistical bias). After a careful evaluation of 
the seven pre- defined areas and 24 topics, and to avoid 
redundancy, they were grouped in four main areas (study 
design, work outcome domains and instruments, data 
analysis and reporting of results) and 16 topics (figure 1).
For topics 3 and 9, some context is needed. The 
follow- up time for outcome assessment should be suffi-
cient to capture changes in the work outcome of interest 
(topic 3). While for presenteeism and sick leave respon-
siveness was demonstrated at 24 weeks of follow- up,11 for 
work status, a follow- up of at least 1 year is preferred. In 
Figure 1 Representation of the 16 pre- defined topics (1 to 16) grouped by the four main methodological areas (A to D).
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fact, changes in work status can only be detected over 
shorter follow- up periods of ≤6 months if large sample 
sizes are used. Work status change and, more precisely, 
transitions between employment and unemployment can 
be seen as formally the last step in a sequence of events 
that start with presenteeism and/or absenteeism.12 On 
the other hand, regarding the recall of the assessment 
instrument (topic 9), there is evidence that a recall period 
beyond 3 months for sick leave becomes inaccurate8 13 and 
that patients prefer a recall of 1 week for presenteeism 
(with maximal accuracy for a 4- week recall).14
Two searches were conducted according to the PICOT 
(Population, Intervention, Comparator, Outcomes, Time 
of follow- up) framework—details are provided in online 
supplemental figure S1. Search 1 focused on studies 
with WP as outcome domain in IA, aiming at critically 
appraising methodological choices and heterogeneity 
across studies, and search 2 on SLRs of studies with WP 
as outcome domain in other chronic diseases, aiming to 
identify whether our pre- identified methodological issues 
in studies in IA were also recognised in other chronic 
diseases and/or new aspects were revealed.
For search 1, the following study designs were included: 
randomised controlled trials (RCTs), controlled clinical 
trials and prospective observational studies (including 
registries). Also, studies in IA assessing costs of changes 
in work participation were identified and included in 
order to assess whether volumes of work productivity 
(eg, days, hours) were reported as a separate step before 
converting volumes into costs.15 Other specific method-
ological aspects related to this particular type of study 
were considered beyond the scope for the current review. 
Exclusion criteria for both searches are provided in 
online supplemental text S1.
The search strategies were designed by an experienced 
librarian (LF). MEDLINE, EMBASE, CINAHL and the 
Cochrane Library were searched (details on search strat-
egies in online supplemental text S2 and S3) between 
January 2009 and May 2019.
Study selection and data extraction
For both searches, references and abstracts were 
imported into the reference management software 
EndNote V.X7.0.2 and deduplicated.
As a high number of hits resulted from the initially 
defined broad timeframe (n=7715), it was decided to 
limit the review to recent studies published from January 
2014 to April 2019 (n=5534). This decision was based 
on feasibility and with the rationale that the most recent 
studies would likely be of better methodological quality 
and better reflect current standards.
Two researchers (MLM and MMtW) independently 
screened all titles and abstracts. Next, full texts were 
reviewed to determine eligibility. Disagreements were 
resolved by discussion, and if necessary, the methodolo-
gists (SR and PP) were involved to make a final decision.
For both searches, study details and results of eligible 
studies were retrieved by two reviewers (MLM and AA) 
using a standardised data extraction sheet. Both reviewers 
(MLM and AA) retrieved data from a 20% random selec-
tion of all the included studies. Given an agreement of 
89% and consensus on how to further avoid divergences 
in data extraction, reviewers continued to independently 
retrieve data of the remaining studies.
For studies in IA, general characteristics of the studies 
were first retrieved, such as the type of study (RCTs vs 
longitudinal observational studies), type of intervention 
(pharmacological intervention, non- pharmacological 
intervention and natural course of the disease), assessed 
WP outcome domain (work status and/or sick leave and/
or presenteeism) and also if the WP outcome domain 
was assessed as primary or secondary outcome (online 
supplemental table S1). Then, the methodological 
choices regarding the 16 pre- defined topics (figure 1) 
were retrieved by area: study design (table 1), work 
outcome domains and instruments (table 2), data anal-
ysis (table 3) and reporting of results (table 4).
For SLRs in other chronic diseases, all the methodolog-
ical issues, as reported by the authors of the SLRs, were 
retrieved and categorised into the 16 pre- defined topics 
(figure 1). The quality of the SLRs was not assessed as 
we were interested in reviewing which methodological 
flaws were reported in other chronic diseases, particu-
larly focusing on new aspects not previously identified 
in IA studies. Both SLRs were registered in PROSPERO 
(CRD42020186798).
RESULTS
For the SLR in IA, the literature search yielded 7715 
hits. After removing duplicates, conference abstracts 
and publications before 2014, 2427 articles remained for 
screening of titles and abstracts, leading to screening of 
132 full- text articles. Twenty- three studies on costs of WP 
were cross- sectional or retrospective and therefore did 
not comply with inclusion criteria to assess general meth-
odological choices. A total of 81 studies were included 
in our analysis (flowchart in online supplemental 
figure S2): 58 for extraction of general methodological 
choices,16–73 23 for outcome reporting studies on costs of 
work productivity16 74–96 and one providing information 
on both outcomes.16
The search for SLRs in other chronic diseases yielded 
10 208 hits. After excluding duplicates and studies before 
2014, 3547 titles and abstracts were screened, resulting 
in screening of 148 full- text articles, and finally 24 were 
included in the analysis (flowchart in online supple-
mental figure S3).97–120
General characteristics of the included studies
The 58 IA studies appraising general methodolog-
ical issues comprised 46 longitudinal observational 
studies16 17 20 23 26 27 29–31 33 34 39–47 50 51 55–59 61 63 65 66 68 70–73 
and 22 RCTs.18 19 21 22 24 25 28 32 35–38 48 49 52–54 60 62 64 67 69 The 
characteristics of included studies are provided in online 
supplemental table S1.
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Most of the IA studies were on rheumatoid arthritis 
(RA) (n=33, 57%),16 17 21–24 27–29 31–34 36 37 39–41 44–47 49 52–54 56 
 57 61 64 68 69 72 followed by axial spondyloarthritis (axSpA) 
(n=16, 28%)18 19 30 38 50 51 59 60 62 63 65–67 70 71 73 and psoriatic 
arthritis (PsA) (n=6, 10%),25 35 43 48 55 58 and finally, two 
studies assessed two diagnostic groups: RA and axSpA,42 
and axSpA and PsA.26
The type of intervention and WP outcome domain for 
each study is presented in online supplemental table S1, 
and the corresponding data grouped by type of study 
Table 1 Methodological choices in the area of ‘study design’
Topics
Results from studies in inflammatory arthritis (n=58)
Aspects identified by authors of SLRs in 
other chronic diseases (n=24)
n/N (%) Detailed information n* (%) Comments
1. The included 
population aligned 
with the work- related 
study objective
16/58 (28%) The included population specifically aligned with the work- 
related study objective in 16/58 (28%) studies (16/28 (57%) 
studies with work as primary outcome)†—n/N§:
 ► 2/21 (10%) RCTs with pharmacological intervention21 22
 ► 1/1 (100%) RCTs with non- pharmacological 
intervention64
 ► 4/13 (31%) OBS with pharmacological 
intervention31 43 44 50
 ► 1/2 (50%) OBS with non- pharmacological intervention30
 ► 8/21 (38%) OBS on the natural course of the 




Lack of clarity on the 
recruitment procedure98 115 120
Study population not 
representative100 114 120
Study population too 
heterogeneous114 115 119
2. Sample size 
calculated for 
the work- related 
outcome
8/58 (14%) The sample size for the work- related outcome was 
calculated in eight studies (8/28 (29%) studies with work as 
primary outcome)†—n/N§:
 ► 1/21 (5%) RCTs with pharmacological intervention21
 ► 1/1 (100%) RCTs with non- pharmacological 
intervention64
 ► 4/13 (31%) OBS with pharmacological 
intervention44 56 58 68
 ► 2/2 (100%) OBS with non- pharmacological 
intervention30 42




No sample size calculation in 
included studies115–117
Study population too small99 
100 103 114
No mention to the sample size 
calculation (if performed or not 
by included studies)97–114 118–120
3. Time horizon 
accurate for the work 
outcome of interest
56/58 (97%) The time- horizon aligned with the work outcome domain of 
interest in 57/58 (98%) studies—n/N§:
 ► Follow- up ≤6 months:
Work status‡: 2/17 (12%)21 52
Sick leave and/or presenteeism: 13/52 (25%)19 28 31 32 35 37 43 
48 52 54 58 67 71
 ► Follow- up >6≤12 months:
Work status‡: 5/17 (29%)21 30 36 42 51
Sick leave and/or presenteeism: 13/52 (25%)18 20 21 36 38 42 51 




Follow- up was reported as:
Highly heterogeneous across 
studies97 114
Too short to assess work 
outcomes111 117 120
Not done/not described106 108 
114 115
Topics Results from studies in inflammatory arthritis (n=58) Aspects identified by authors of SLRs in 
other chronic diseases (n=24)
n/N (%) Detailed information n* (%) Comments
3. Time horizon 
accurate for the work 
outcome of interest 
(continuation)
 ► Follow- up >12 months:
Work status: 11/17 (65%)16 23 27 40 41 46 50 53 57 62 70
Sick leave and/or presenteeism: 26/52 (51%)16 17 22 24–27 29 33 
34 39 44–47 49 50 53 59 60 62 65 66 69 72 73
  
4. Use of a 
comparator
26/58 (47%) A comparator was used in 26/58 studies (47%)—n/N§:
 ► 21/21 (100%) RCTs with pharmacological 
intervention18 19 21 22 24 25 28 32 35–38 48 49 52–54 60 62 67 69
 ► 1/1 (100%) RCT with non- pharmacological intervention64
 ► 2/13 (15%) OBS with pharmacological intervention51 71
 ► 2/2 (100%) OBS with non- pharmacological 
intervention30 42
 ► 0/21 (0%) OBS on the natural course of the disease
3 (12%)
1 (4%)
Most studies lacked a control 
group97 102 114
Unmatched control groups114
*Number of systematic literature reviews reporting on the corresponding topic.
†7/28 (25%) studies with work as primary outcome included unselected patients from registries.
‡Emery et al (2016) have two different time horizons because this is a post hoc analyses of two trials: time horizon of 26 and 24 weeks for the 
Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab (OPTIMA) and PRevention Of Work Disability (PROWD) trials, 
respectively.
§The denominator may vary according to the type of intervention, work outcome of interest or type of study.
n/N, number of original studies in which the methodological choice was identified/number of studies in which the topic was possible to assess; 
OBS, observational longitudinal study; RCT, randomised controlled trial.
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(RCTs vs longitudinal observational studies) is shown 
in online supplemental table S2. Work was assessed 
as a primary outcome in only 26/58 (45%) of the 
studies,16 17 21 23 26 27 29–31 41 42 44–47 50 56–58 61 63 64 66 68 71 rarely 
being the primary outcome in RCTs (n=2/22, 9%).21 64 
The time horizon for the assessment of WP outcomes 
varied from 24 weeks to 12 years and its distribution, as 
well as the frequency of assessment by work outcome 
domain, are both provided in online supplemental table 
S3.
The general characteristics of included SLRs are 
presented in online supplemental table S4. Most studies 
focused on cancer (n=15; 63%),98 99 101 105–109 111 112 115 116 118–120 
followed by stroke (n=3, 13%).97 113 117 The most frequently 
Table 2 Methodological choices in the area of ‘work outcome domains and instruments’
Topics
Results from studies in inflammatory arthritis (n=58)
Aspects identified by authors of SLRs 
in other chronic diseases (n=24)
n/N* (%) Detailed information n† (%) Comments
5. Work outcome 
domains defined
52/58 (90%) The work outcomes domain was defined in 51 
studies—n/N* (%):
 ► Work status: 12/17 
(71%)21 23 27 30 40 41 46 50 53 57 62 70
 ► Sick leave: 46/46 
(100%)16 18–22 24–27 29 31–39 42–47 49–56 58–60 63 65–69 71–73
 ► Presenteeism: 39/40 
(98%)17–21 24–26 28 31–39 42 43 48 50–56 58–64 67–69 71 73
13 (54%) High variability in the 
definition of a work 
outcome in included studies 
precluding data pooling/
meta- analysis97–99 102 105–107 
109 111 113 114 117 120
6. Validated 
measurement of sick 
leave
42‡/46 (91%) Of the studies that had sick leave as work outcome 
domain, 42 used validated instruments to assess it, 
n/N (%):
 ► WPAI: 29‡/46 
(63%)18–21 24–26 31–34 36–39 42 43 50–53 55 56 58 63 67 69 71 73
 ► WPS: 5‡/46 (11%)35 39 54 60 68
 ► Workdays missed due to IA (long- term 
sick leave assessed in registries): 9/46 







35‡/40 (88%) Of the studies that had presenteeism as work 
outcome domain, 35 used validated and OMERACT 
endorsed instruments, n/N* (%):
 ► WPAI: 29‡/40 
(73%)18–21 24–26 31–34 36–39 42 43 50–53 55 56 58 63 67 69 71 73
 ► WLQ-25: 2/40 (5%)61 64
 ► WPS: 5‡/40 (13%)35 39 54 60 68
 ► WALS: 0/40 (0%)
 ► WAI: 0/40 (0%)
1 (4%)
1 (4%)
WPAI used only in a small 
number of studies119
Studies use qualitative, 
quantitative and economic 
non- standardised measures 
of work productivity119
8. Attribution of work 
participation to overall 
health
29/58 (50%) The work outcome domain was assessed in relation 
to overall health (and not in relation to IA) in 46 
studies, n/N* (%):
 ► Work status: 8/17 (47%)16 27 30 40 42 46 51 57
 ► Sick leave: 23/46 
(50%)16 18 20 22 25 27 29 31 33 34 38 42 44–47 49 51 55 58 65 67 72
 ► Presenteeism: 15/40 




Topics Results from studies in inflammatory arthritis (n=58) Aspects identified by authors of SLRs 
in other chronic diseases (n=24)
n/N* (%) Detailed information n/N* (%)
9. Recall period 
of self- reported 
sick leave and 
presenteeism
35/42 (82%) The recall period of self- reported sick leave was ≤3 
months in 34/37 (92%) studies (excluding registries 
as recall is not applicable)18–21 24–26 31–39 42 43 50–56 58–60 
63 67–69 71 73
The recall period of self- reported presenteeism was 
of 7 days to 1 month in 34/40 (85%) studies18–21 
24–26 31–39 42 43 50–56 58 60 62 63 67–69 71 73
1 (4%)
2 (8%)
Inconsistency of the recall 
period103
No accounting for a possible 
recall bias102 115
*The denominator may vary according to the corresponding assessed topic.
†Number of systematic literature reviews reporting on the corresponding topic.
‡Boer et al (2018) used both WPAI- RA and WPS- RA.
IA, inflammatory arthritis; n/N, number of original studies in which the methodological choice was identified/number of studies in which 
the topic was possible to assess; WALS, Workplace Activity Limitations Scale; WLQ-25, Work Limitations Questionnaire 25- item; WPAI, 
Work Productivity and Activity Impairment; WPS, Work Productivity Questionnaire.
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assessed work outcome was ‘return to work after a tempo-
rary absence’ (n=12, 50%).97 99 101 107–110 113 115–117 120
Study design
Table 1 provides an overview of methodological choices 
in the area of study design. The included population was 
aligned with the specific work- related study objective in 
only 16/58 (28%) IA studies,21–23 26 27 30 31 43–46 50 61 63 64 66 
while the sample size calculation was performed solely in 
8 (14%) studies.21 30 42 44 56 58 64 68
Large heterogeneity was observed in the follow- up time 
of the IA studies, although the majority of studies assessed 
changes in work status within a follow- up of >6 months. 
Of the five studies assessing changes in work status over 
an unrealistic short follow- up period ≤6 months,21 30 52 53 67 
two also assessed it after 12 months (online supplemental 
table S3).30 53
The frequency of assessment of sick leave in obser-
vational studies (excluding registries, n=8) was longer 
than 3 months in more than half of the studies (12/20 
(60%))20 26 33 34 39 42 50 51 59 63 66 72; however, the other 8/20 
(40%) had a frequency of assessment shorter than 3 
months hampering correct aggregation into cumulative 
sick leave.31 43 55 56 58 68 71 73
While all RCTs had a compar-
ator,18 19 21 22 24 25 28 32 35–38 48 49 52–54 60 62 64 67 69 only 8/36 
(22%) observational studies had one.27 29 30 42 46 51 70 71
The general population, a meaningful benchmark in 
studies with work as an outcome, was used as a compar-
ator solely in five observational studies.27 29 30 46 70
Regarding SLRs in other chronic diseases, similar 
issues were reported for all the topics of study design, 
with the most common flaw being no mentioning of the 
sample size calculation for work as outcome, as reported 
in 21/24 (87%) SLRs.97–114 118–120
Work outcome domains and instruments
The methodological choices regarding the work 
outcome domains and instruments are presented in 
table 2. Among studies in IA, the definition of 
Table 3 Methodological choices in the area of ‘data analysis’
Topics
Results from studies in inflammatory arthritis (n=58)
Aspects identified by authors of SLRs 
in other chronic diseases (n=24)
n/N* (%) Detailed information N† (%) Comments
10. Accounting for 
skewness of the 
outcome
10/‡52 (19%) Sick leave is reported as positively skewed (zero- inflated) 
in 10/46 (22%) studies. The authors accounted for 
skewness by:
 ► Dichotomising the outcome: 2/10 (20%)20 63
 ► Analysing the outcome as categorical variable: 2/10 
(20%)46 50
 ► Using non- parametric bootstrapping: 4/10 
(40%)22 45 47 65
 ► Using zero- inflated models‡: 2/10 (20%)58 59
Presenteeism was reported as zero- inflated in 1/40 (3%) 
study. The authors accounted for skewness by using zero- 
inflated models‡; 1/1 (100%)58
Not reported –
11. Accounting for 
interdependence of 
outcomes
49/52§ (94%) Interdependence was accounted for in 49 studies by—
n/N*:
 ► Assessing sick leave only among employed patients: 
43/46 (93%)18–22 24–27 29 31–39 42–47 50–56 58–60 63 65–69 71 73
 ► Assessing presenteeism among employed 
patients that were not in sick leave: 37/40 
(90%)18–22 24–26 31–39 42 43 50–56 58–60 62–64 67–69 71 73
Not reported –
12. Accounting for 
contextual factors
25/58 (43%) Contextual factors were accounted for in 8/22 (36%) 
RCTs and 17/36 (47%) OBS—n/N*:
 ► As covariates/confounders¶
Personal factors: sociodemographics (7/8 RCTs,19 25 36 37 
49 67 69 88% and 15/17 OBS,16 20 27 41 44 46 50 56–58 61 65 66 70 72 
88%)
Work- related factors: workplace support (1/17 OBS50, 
6%), nature of work (4/17 OBS,27 41 58 70 24%)
 ► Effect modification¶
Personal factors: sociodemographics (1/8 RCT,52 13% 
and 2/17 OBS,23 63 12%)
Work- related factors: nature of work (1/17 OBS,63 6%)
12 (50%) Adjustment for 
contextual/confounder 
factors in the included 
studies, if any, is 
performed only for very 
few factors
101 105 107 109 110 112–117 120
*The denominator may vary according to the topic assessed.
†Number of systematic literature reviews in other chronic diseases in which the authors report on the corresponding topic.
‡Tillet et al (2017) accounted for skewness of both sick leave and presenteeism.
§Studies addressing work status only were excluded from the denominator as interdependence between work outcome domains does not apply to 
them.
¶Different contextual factors may have been accounted for in the same study.
n/N, number of original studies in which the methodological choice was identified/number of studies in which the topic was possible to assess; 
OBS, observational longitudinal study; RCT, randomised controlled trial.
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‘work status’ was described in two- thirds of studies 
(71%)21 23 27 30 40 41 46 50 53 57 62 70 and definitions showed 
large heterogeneity. Sick leave was defined in all studies 
assessing it,16 18–22 24–27 29 31–39 42–47 49–56 58–60 63 65–69 71–73 and 
all but one reported the definition of presenteeism.30
SLRs in other chronic diseases reported high variability 
in the definition of all WP outcomes in included studies 
precluding meta- analysis.97–99 102 105–107 109 111 113 114 117 120 In 
contrast, the majority of studies in IA assessed sick leave 
and presenteeism using validated instruments—91% 
and 88% of studies, respectively. The Work Productivity 
and Activity Impairment (WPAI) questionnaire was the 
outcome measurement instrument most frequently used 
(n=29).18–21 24–26 31–34 36–39 42 43 50–53 55 56 58 63 67 69 71 73
Overall, the work outcome domains’ attribution (to 
overall health, arthritis or no attribution) was heteroge-
neous across studies, with sick leave being the domain most 
frequently assessed in relation to overall health (23/46 
(50%) studies).16 18 20 22 25 27 29 31 33 34 38 42 44–47 49 51 55 58 65 67 72
Reviews in other chronic diseases pointed out incon-
sistencies of the recall period (varying from 7 days to 7 
years).102 103 115 On the contrary, in IA, the recall period of 
sick leave (excluding registries since recall is not applicable) 
was accurate8 13 (ie, ≤3 months—figure 1) in 34/37 (92%) 
studies,18–21 24–26 31–39 42 43 50–56 58–60 63 67–69 71 73 and the recall of 
presenteeism was reliable and in line with the face validity 
for patients14 (ie, between 7 days and 4 weeks—figure 1) in 
34/40 studies (85%).18–21 24–26 31–39 42 43 50–56 58 60 62 63 67–69 71 73
Data analysis
Regarding the methodological choices in the area of 
data analysis (table 3), only 10/53 (19%) IA studies 
reported skewness of sick leave and/or presen-
teeism and accounted for the skewness in the anal-
yses.20 22 45–47 50 58 59 63 65
Also, only 8/22 (36%) RCTS19 25 36 37 49 52 67 69 and 17/36 
(47%) observational studies16 20 23 27 41 44 46 50 56–58 61 63 65 66 70 72 
took contextual factors into account, most frequently 
demographic factors, such as age and gender, while other 
specific work- related contextual factors (eg, nature of work 
and workplace support) were less frequently accounted 
for.27 41 50 58 63 70 SLRs in other chronic diseases reported 
that adjustment for contextual factors/confounders in 
the included studies, if any, was performed for very few 
factors.101 105 107 109 110 112–117 120
The majority of studies in IA (n=49/52, 94%) 
took interdependence between work outcomes into 
account acknowledging that (1) data (over time) 
on sick leave are less meaningful without informa-
tion on the proportion of persons employed (over 
time) in that specific population (sick leave cannot 
happen if the person is not employed) and/or (2) 
assessing presenteeism is less meaningful if informa-
tion on sick leave is not provided (eg, presenteeism 
cannot happen on days a person is absent due to sick 
leave).18–22 24–27 29 31–39 42–47 50–56 58–60 62–69 71 73
Table 4 Methodological choices in the area of ‘reporting of results’
Topics
Results from studies in inflammatory arthritis 
(n=58)
Aspects identified by authors of SLRs in 
other chronic diseases (n=24)
N/N* (%) Detailed information N† (%) Comments
13. Work- related drop- 




Reported loss to follow- up and 
work- related reasons for drop- 
out50
2 (8%) Attrition and its reasons are 
inconsistently reported: described 
as well reported in 1 SLR118and 
inadequately reported in the 
other112
14. The size and 
characteristics of the 
(sub)groups analysed are 
described
58/58 (100%) All studies reported the size and 
characteristics of the analysed 
(sub)groups16–73
1 (4%) No subgroup analysis is performed 
in included studies104
15. Group level and 
patient level presented
11/58 (19%) Presented both aggregated 
results (group level) and 
percentages according to 
meaningful thresholds (patient 
level)19 30 35 42 51 56 59 62 65 66 71
1 (4%) Lack of patient- level data precluded 
meta- analysis104
16. Volumes of production 
loss reported in cost 
studies
21/24‡ (88%) Of the studies reporting 
productivity costs, 88% 
provided data on natural 
volumes (days/hours) used to 





*The denominator may vary according to the topic assessed.
†Number of systematic literature reviews in other chronic diseases in which the authors report on the corresponding topic.
‡The denominator corresponds to the studies reporting productivity costs.
n/N, number of original studies in which the methodological choice was identified/number of studies in which the topic was possible to 
assess.
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Reporting of results
The methodological choices in IA studies as well as the 
issues raised in SLRs in other chronic diseases regarding 
the area of reporting are described in table 4.
The reporting loss to follow- up and the work- related 
reasons for drop- out were often neglected in IA studies, 
being reported in only one study.50 In other chronic 
diseases, this was also inconsistently reported.112 118
All IA studies reported the size and characteristics of 
the (sub)groups analysed.16–73
In IA studies, the choice on how to report study 
findings was heterogeneous, with only 11/58 (16%) 
studies presenting both aggregated results (mean/
median) and percentages according to meaningful 
thresholds.19 30 35 42 51 56 59 62 65 66 71 This was also outlined 
by the SLRs in other chronic diseases where the lack 
of patient- level data was a barrier to study pooling and 
meta- analysis.104
Data on natural volumes (days/hours) used to calculate 
costs was presented in the majority of the studies reporting 
productivity costs (21/24, 88%).16 74–76 78–82 84–92 94–96
DISCUSSION
WP has been a frequently assessed endpoint in IA studies 
over the past 5 years; however, these studies revealed a 
high methodological heterogeneity and a number of 
important flaws. Several issues were detected in the areas 
of study design, work outcome definition and assessment, 
as well as in the analysis and reporting of the results. 
Review of SLRs in other chronic diseases revealed that 
observed methodological issues are not rheumatology 
specific as these are also common in studies of work 
outcomes in other clinical fields.
Different WP outcomes of interest apply to specific 
subpopulations (eg, employed/employable people) and 
need to be assessed in a sufficiently large group over a 
certain timeframe.4 Notwithstanding, this was often 
neglected, particularly when WP was not the primary 
outcome as occurred in the majority of RCTs. Thus, the 
studied population, the intermediate assessment time- 
points and overall follow- up time were tailored on the 
primary outcomes, hampering the power to detect statis-
tically significant effects on WP outcomes and leading 
to follow- up times not adequate for some of the WP 
outcomes of interest. Moreover, even in RCTs with long- 
term extensions, WP outcome domains were not assessed 
across the extension study period as other outcomes. 
This pose particular challenges in studies aiming to 
understand the impact of an intervention on long- term 
employment, work disability or prolonged sick leave 
(eg, assessing costs of productivity loss), as having a time 
horizon of 6 months is not adequate.8 Remarkably, also 
studies with WP as the primary outcome had important 
flaws in this area, for example, the sample size calculation 
was often not reported.
Careful choice of which WP outcome to assess and 
which measurement instrument to use is of paramount 
importance, particularly when dealing with a comparison 
of interventions.8 9 As far as the definition of employment 
and work disability is concerned, clinical studies might 
want to align with definitions that are relevant for their 
administrative entities (eg, countries, regions, states, etc),8 
thus likely contributing to heterogeneity in work status 
definitions as found in IA studies. In contrast, presen-
teeism and sick leave were often described in line with 
the frequent use of validated instruments (eg, WPAI) that 
include an appropriate definition for the work outcome 
domain.8 In this regard, stakeholders should strive to 
harmonise worldwide comparable and locally appli-
cable definitions along with endorsing specific outcome 
measurement instruments, for example, as OMERACT is 
doing for presenteeism.8 9 Two other important method-
ological aspects, namely, disease attribution and recall, 
are relevant but not (yet) encompassed by the OMERACT 
framework. Regarding disease attribution, only half of 
the studies assessed the WP outcome domain in relation 
to overall health (more meaningful for benchmarking 
with the general population). This may be problematic 
since it is well established that patients have difficulties 
in distinguishing which restrictions can be attributable 
to IA, other specific health problems (eg, osteoarthritis) 
or overall health.5 Inconsistency of the recall period 
was often reported in studies of other chronic diseases, 
however less evident in IA studies. This is likely due to the 
widespread use of validated instruments such as WPAI 
(past 7 days recall) and the Work Productivity Survey 
(WPS; past month recall) in the field of rheumatology.
WP, as any outcome, is subject to the effect of a number 
of variables, related to either the disease, the social envi-
ronment or other aspects, which require to be considered 
in order to reliably assess the net change of the outcome. 
Contextual factors, defined by OMERACT, from a statis-
tical viewpoint, as a “variable that is not an outcome of 
the study but needs to be recognized (and measured) 
to understand the study results”, include potential 
confounders and effect modifiers (https:// omeract. 
org/ handbook- resources/). The characterisation of core 
contextual factors (ie, when do they really matter to influ-
ence practice) remains a challenge, partially because 
the influence of most contextual factors tends to vary 
according to the setting.8 The International Classification 
of Functioning, Disability and Health (ICF) provided, in 
addition to the bio- psycho- social framework, also a clas-
sification distinguishing personal and environmental 
factors, and this was the basis for a further grouping of 
contextual factors relevant for WP by the OMERACT 
work productivity group.10 Lack of accounting for contex-
tual factors was common in IA and often reported also by 
SLRs in other chronic disease. Work- related contextual 
factors such as job type, adaptations at work and more 
personal aspects such as ability to cope and satisfaction 
were often neglected. This emphasises the urgent need 
of action for improving and implementing feasible strat-
egies to account for relevant work- related contextual 
factors.
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Other methodological issues pertain to how data are 
analysed and reported. WP presents a continuum of 
subdomains which are (hierarchically) dependent on 
each other and/or can compete over time.5 The majority 
of studies assessing sick leave and presenteeism took 
interdependence between work outcomes into account, 
encompassing the widespread use of the WPAI, which 
already considers interdependence of sick leave and 
presenteeism (overall work impairment). SLRs in other 
chronic diseases reported that despite using the correct 
instrument (eg, WPAI), the studies frequently neglected 
some important subdomains.119 Indeed, to account for 
interdependence, WPAI must be comprehensively used, 
that is, assessing both presenteeism and sick leave plus 
the overall work impairment. Yet, consensus is needed on 
how to deal with such dependencies when instruments 
other than WPAI are used. It is known that distribution 
of presenteeism, and especially sick leave, may often be 
highly skewed (even zero inflated).6 7 Not accounting for 
this, as we observed in the majority of studies, may affect 
the robustness of conclusions.
Furthermore, drop- out may be related to underlying 
work context and thus not be at random, so the rates and 
reason for drop- out should be carefully considered to 
ensure a correct interpretation of the impact of IA on WP 
outcomes overtime. However, these were not reported in 
the majority of studies. Likewise, to enhance the insight 
into WP outcomes and to ensure more transparent inter-
pretation of the differences between interventions, the 
mean and median values of sick leave or presenteeism 
and also the proportion of patients attaining a specific 
meaningful (change in) outcome are advisable to report.8 
In IA studies, the choice on how to report data on work 
outcome domains was heterogeneous, with only 19% of 
studies presenting both aggregated results and percent-
ages according to meaningful thresholds. Choice of 
thresholds was not uniform across studies, highlighting 
the needs for consensus in this respect.
This review has some limitations. Although we used 
a sensitive approach to identify studies with WP as an 
outcome domain in IA as well as SLRs in other chronic 
diseases, we cannot be sure that some relevant studies 
were missed. While retrieving data from SLRs in other 
chronic diseases, only the reported issues were collected, 
as going through the primary studies was beyond the 
scope. This may have resulted in missing some relevant 
methodological aspects not captured by the SLR authors. 
The exclusion of studies <2014 due to feasibility reasons 
implies that our summary is generalisable to issues found 
in recent studies.
In conclusion, a high methodological heterogeneity 
and important flaws were detected among the included 
studies in the main areas of study design, work outcome 
definition and assessment, analysis and reporting of 
results. This SLR alerts for the need of implementation 
of minimum quality standards around these key method-
ological aspects to homogenise and improve the quality 
of future studies in IA and likely in other chronic diseases. 
This review informs the EULAR Points to Consider for the 
conduction, analysis and reporting of studies with work 
as an outcome domain in IA.
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